Schonfeld Strategic Advisors LLC Sells 148,900 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Schonfeld Strategic Advisors LLC decreased its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 91.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,400 shares of the biopharmaceutical company’s stock after selling 148,900 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Revance Therapeutics were worth $41,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of RVNC. Natixis acquired a new position in Revance Therapeutics during the fourth quarter worth about $31,000. Two Sigma Securities LLC acquired a new position in Revance Therapeutics during the fourth quarter worth about $35,000. Alpine Global Management LLC acquired a new position in Revance Therapeutics during the fourth quarter worth about $37,000. RPO LLC acquired a new position in Revance Therapeutics during the fourth quarter worth about $55,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Revance Therapeutics during the fourth quarter worth about $74,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on RVNC. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. StockNews.com initiated coverage on Revance Therapeutics in a report on Tuesday. They set a “hold” rating on the stock. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.45.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Thursday. The stock has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The stock’s 50-day moving average is $3.65 and its 200-day moving average is $3.72. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $6.65.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.